Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Modest Clinical Benefit Is Observed With or Without Bevacizumab Added to Atezolizumab/Chemotherapy in BTC Signal Seeking Study

January 21st 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

Tislelizumab Provides QOL Benefit Over Sorafenib in Unresectable HCC

January 21st 2023

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

Sorafenib Plus SBRT Improves Survival in Locally Advanced HCC

January 21st 2023

The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.

Nab-Paclitaxel Plus Gemcitabine/Cisplatin Does Not Significantly Improve OS in Newly Diagnosed, Advanced Biliary Tract Cancers

January 21st 2023

The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.

Frontline NALIRIFOX Elicits OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma

January 21st 2023

First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.

Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma

January 20th 2023

Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

January 20th 2023

Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.

bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCC

January 20th 2023

Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.

Promising Efficacy and Safety Demonstrated With Envafolimab, Lenvatinib, and TACE in Unresectable HCC

January 20th 2023

Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.

Anti-drug Antibodies Do Not Affect Durvalumab Alone, With Tremelimumab in Unresectable HCC

January 20th 2023

The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.

LEAP-002 HRQOL Analysis Shows Comparable Scores with Pembrolizumab/Lenvatinib Vs Lenvatinib/Placebo in HCC

January 20th 2023

In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.

Lenvatinib Following Progression on Immunotherapy Demonstrates Efficacy in Second-line HCC

January 20th 2023

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

Early Exploration With HER-Vaxx Extends Survival for Patients with HER2+ Gastric/GEJ Adenocarcinoma

January 20th 2023

Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.

Frontline Zolbetuximab/mFOLFOX6 Prolongs Survival in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 20th 2023

Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.

Nivolumab Plus Ipilimumab or Chemo Maintains OS Benefit in ESCC in Long-Term Results

January 20th 2023

Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

Updated CheckMate-649 Data Support Nivolumab/Chemo as Frontline SOC in Advanced Gastric/GEJ/Esophageal Cancer

January 20th 2023

The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.

Neoadjuvant Tremelimumab/Durvalumab Elicits Responses in Gastric/GEJ Adenocarcinoma

January 19th 2023

Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.

HER2-Low Classification Is Associated With Distinct Clinical Features in Advanced Gastric Cancer

January 19th 2023

Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.

Taking a Look Back at Trials From ASCO GI 2022

February 1st 2022

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

January 23rd 2022

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.